Scientific Journal

Scientific Journal of the Hellenic Companion Animal Veterinary Society (HCAVS)

 

Primary hyperlipidemia in a Miniature Schnauzer: a case report


Christoforaki S. Companion Animal Clinic, Unit of Medicine, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki.
Konstantinidis A.O. Companion Animal Clinic, Unit of Medicine, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki
Pardali D. Diagnostic Laboratory, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki
Soubasis N. Companion Animal Clinic, Unit of Medicine, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki
Adamama-Moraitou K.K. Companion Animal Clinic, Unit of Medicine, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki

Introduction

Primary or Idiopathic (IH) hyperlipidemia is common in Miniature Schnauzers and is characterized by moderate or severe fasting hypertriglyceridemia with or without concurrent hypercholesterolemia. The aim of this report is to present the diagnosis and treatment of IH in a Miniature Schnauzer.

Clinical case

An 8.5-years-old, sprayed female, Miniature Schnauzer presented with a history of intermittent anorexia, vomiting, large bowel diarrhea, and hypertriglyceridemia despite being on an ultra lowfat diet. Clinical and laboratory examination revealed only severe hypertriglyceridemia and mildly elevated serum liver enzymes activity (ALP, ALT). All possible causes of hyperlipidemia were excluded.

Results

Diagnosis of IH of Miniature Schnauzers was established. The dog treated with fenofibrate (10 mg/ kg; SID) in combination with an ultra low-fat diet. Triglyceride concentrations normalized shortly after fenofibrate initiation. The dog experienced several adverse effects (anorexia, regurgitations, vomiting and large bowel diarrhea) which resolved upon discontinuation of treatment. Dose reduction of fenofibrate (2.5 mg/kg; SID) was sufficient to control triglyceride levels without experiencing any side effects.

Conclusions

This is the first case of a Miniature Schnauzer with hypertriglyceridemia in Greece and IH should be included in the differential diagnosis. Fenofibrate can cause several side effects; however, it is effective in lower than indicated doses.

References

  • Xenoulis PG, Steiner JM (2015) Canine hyperlipidaemia. Journal of Small Animal Practice 56, 595–605.
  • Munro MJL, Hulsebosch SE, Marks SL, Gilor C (2021) Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipi- demia in dogs. J Vet Intern Med 2021, 1–10.
  • Xenoulis PG, Steiner JM (2010) Lipid metabolism and hyperlipidemia in dogs. The Veterinary Journal 183, 12–21.
  • Miceli DD, Vidal VP, Blatter MFC, Pignataro OP, Castillo VA (2021) Fenofibrate treatment for severe hypertriglyceridemia in dogs. Domestic Animal Endocrinology 74, 106578.
  • Xenoulis PG, Suchodolski JS, Levinski MD, Steiner JM (2007) Investigation of hypertriglyceridemia in healthy Miniature Schnauzers. J Vet Intern Med 2007 21, 1224–1230.

Quick Links

Social Media

Contact us

Hellenic Journal of
Companion Animal Medicine

Apollo Tower
64 Louizis Riankour Street,
115 23 Athens
Tel.: +30 210 7759727
Fax.: +30 210 7753460
iatrikizs@hcavs.gr

Sponsor

 
diagnovet